Figure 5.

Sensitivity of PDOs derived from HER2-negative breast cancer patients to docetaxel and anthracyclines. (A,C): The bright field shows the changes in the size and status of HER2-negative organoids after treatment with different drug concentrations of docetaxel and epirubicin (the upper row represents the organoids treated without the drugs, and the lower row represents the organoids treated with different drug concentrations for six days). Scale bar, 150 mm. (B): The line graph shows the survival rate of HER2-negative organoids treated with different drug concentrations of docetaxel and epirubicin. (D): Comparison of the sensitivity of HER2-negative organoids from the biopsy sample to epirubicin, and the logIC50 of each type of organoid to epirubicin.